SandoSTATIN 500 mcg in 1 mL Injection
RxNorm 207200
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 207200 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: SandoSTATIN 500 mcg in 1 mL Injection.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SBDPrescribable
Semantic Branded Drug (SBD):
1 mL octreotide 0.5 mg/ML Injection [Sandostatin]
(Atom ID: 12371329)
TMSYPrescribable
Tall Man Lettering Synonym (TMSY):
1 mL octreotide 0.5 mg/ML Injection [SandoSTATIN]
(Atom ID: 12380102)
SYPrescribable
Synonym (SY):
1 mL Sandostatin 0.5 mg/ML Injection
(Atom ID: 7245633)
TMSYPrescribable
Tall Man Lettering Synonym (TMSY):
1 mL SandoSTATIN 0.5 mg/ML Injection
(Atom ID: 7245941)
PSNPrescribable
Prescribable Name (PSN):
SandoSTATIN 500 mcg in 1 mL Injection
(Atom ID: 7246643)
SYPrescribable
Synonym (SY):
Sandostatin 500 mcg per 1 mL Injection
(Atom ID: 7246642)
TMSYPrescribable
Tall Man Lettering Synonym (TMSY):
SandoSTATIN 500 mcg per 1 mL Injection
(Atom ID: 7246751)
Patient Education
Octreotide Injection
Octreotide immediate-release injection is used to decrease the amount of growth hormone (a natural substance) produced by people with acromegaly (condition in which the body produces too much growth hormone, causing enlargement of the hands, feet, and facial features; joint pain; and other symptoms) who cannot be treated with surgery, radiation, or another medication. Octreotide immediate-release injection is also used to control diarrhea and flushing caused by carcinoid tumors (slow-growing tumors that release natural substances that can cause symptoms) and vasoactive intestinal peptide secreting adenomas (VIP-omas; tumors that form in the pancreas and release natural substances that can cause symptoms). Octreotide long-acting injection is used to control acromegaly, carcinoid tumors, and VIP-omas in people who have been successfully treated with octreotide injection but prefer to receive injections less often. Octreotide injection is in a class of medications called octapeptides. It works by decreasing the amounts of certain natural substances produced by the body.
[Learn More]
* Please review the disclaimer below.